On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Rs. 40 cr buyback, 200% dividend announced
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Subscribe To Our Newsletter & Stay Updated
